Pomalyst (Pomalidomide) Received a New Indication for Patients with Relapsed and/or Refractory Multiple Myeloma

Lignende værker

• Kyprolis (Carfilzomib) Received New Indications as Combination Therapy for Use in Relapsed and/or Refractory Multiple Myeloma
  af: Raedler, Lisa A.
  Udgivet: (2016)
• The role of pomalidomide in treatment of relapse and refractory multiple myeloma
  af: S. V. Voloshin, et al.
  Udgivet: (2022-01-01)
• Bendamustine, pomalidomide, and dexamethasone for relapsed and/or refractory multiple myeloma
  af: Sivaraj, Dharshan, et al.
  Udgivet: (2018)
• Pomalidomide, bortezomib, and dexamethasone for patients with relapsed lenalidomide-refractory multiple myeloma
  af: Paludo, Jonas, et al.
  Udgivet: (2017)
• Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma
  af: Matsue, Kosei, et al.
  Udgivet: (2015)